Author(s):
Lucky B. Vasave, Mayur S. Bhamare, Rushikesh L. Bachhav, Shivraj P. Jadhav3, Sunil K. Mahajan
Email(s):
luckyvasave10@gmail.com
DOI:
10.52711/0975-4377.2025.00029 
Address:
Lucky B. Vasave1*, Mayur S. Bhamare2, Rushikesh L. Bachhav3, Shivraj P. Jadhav3, Sunil K. Mahajan3
1Department of Pharmaceutics, Divine Collage of Pharmacy, Satana, Nashik, Maharashtra, India.
2Affiliated by Savitribai Phule Pune University, Maharashtra 423301, India.
3Divine Collage of Pharmacy, Satana, Nashik, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 3,
Year - 2025
ABSTRACT:
Today, the new approach to pharmaceutical quality is called Quality by Design. This essay provides an overview of pharmaceutical quality by design (QBD) and explains how to apply QBD to guarantee the quality of pharmaceuticals. Several of the components of the Quality by Design are recognized and explained. For every unit operation, process parameters and quality attributes are determined. The advantages, prospects, and procedures associated with pharmaceutical product quality by design are explained. The goal of pharmaceutical development is to create high-quality products and manufacturing processes that reliably produce the desired results. Products cannot be assessed for quality; instead, quality should be included into the design. It contains the Quality target product profile, important Quality characteristics, and important Quality elements through Desing. Additionally, it provides a comparison of the product quality as determined by Quality by Design and as determined by final product testing. The ICH Guidelines serve as the cornerstone of Quality by Design. The Q8 guidelines for pharmaceutical development, Q9 guidelines for quality risk management, and Q10 guidelines for pharmaceutical quality systems form its foundation. It also discusses the use of Quality by Design in the creation and production of medications.
Cite this article:
Lucky B. Vasave, Mayur S. Bhamare, Rushikesh L. Bachhav, Shivraj P. Jadhav, Sunil K. Mahajan. Quality by Design (QBD) in Pharmaceutical Development: A Review of Principles and Case Studies. Research Journal of Pharmaceutical Dosage Forms and Technology.2025; 17(3):203-1. doi: 10.52711/0975-4377.2025.00029
Cite(Electronic):
Lucky B. Vasave, Mayur S. Bhamare, Rushikesh L. Bachhav, Shivraj P. Jadhav, Sunil K. Mahajan. Quality by Design (QBD) in Pharmaceutical Development: A Review of Principles and Case Studies. Research Journal of Pharmaceutical Dosage Forms and Technology.2025; 17(3):203-1. doi: 10.52711/0975-4377.2025.00029 Available on: https://rjpdft.com/AbstractView.aspx?PID=2025-17-3-7
REFERENCES:
1. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Office of Regulatory Affairs (ORA). PAT Guidance for Industry: A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance. September 2004.
2. U.S. Department of Health and Human Services, Food and Drug Administration (FDA). Guidance for Industry: Q8 Pharmaceutical Development. May 2006.
3. Lionberger RA, Lee SL, Lee L, Raw A. Quality by design: Concept for ANDA’s. Am J Pharm Sci. 2008; 10(2): 269-274.
4. Hart C. Doing a literature review: Releasing the social science research imagination. 1998.
5. Grant MJ, Booth A. A typology of reviews: An analysis of 14 review types and associated methodologies. Health Info Libr J. 2009; 26(2): 91-108.
6. Booth A, Sutton A, Papaioannou D. Systematic approaches to a successful literature review. 2016.
7. U.S. Food and Drug Administration (FDA). Pharmaceutical Quality for the 21st Century: A Risk-Based Approach. 2006.
8. International Council for Harmonization (ICH). Q8(R2) Pharmaceutical Development. 2009.
9. Nasr MM, Gokhale R. Quality by Design in the Pharmaceutical Industry. J Pharm Innov. 2008; 3(2): 100-108.
10. Yu LX, et al. Understanding Pharmaceutical Quality by Design. AAPS J. 2008; 10(2): 268–276.
11. International Conference on Harmonisation (ICH). Q8(R2): Pharmaceutical Development. Available at: www.ich.org, 2009.
12. International Conference on Harmonisation (ICH). Q9: Quality Risk Management. Available at: www.ich.org, 2005.
13. Yu LX. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. Pharm Res. 2008; 25(4): 781–791.
14. Montgomery DC. Design and Analysis of Experiments. John Wiley and Sons, 2012.
15. Kumar S, Kothari D, Rathore AS. Process Analytical Technology and Real-Time Quality Control in Biopharmaceutical Manufacturing. Trends Biotechnol. 2014; 32(6): 346–354.
16. Kumar A, et al. Continuous Manufacturing: A Quality by Design Approach. Int J Pharm. 2020;588.
17. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009; 27(1): 26-34.
18. Rathore AS. Quality by design (QBD): An industry perspective. Indian J Pharm Sci. 2008; 70(5): 645.
19. Singh B, Beg S, Sharma G, Jain A, Negi P. Holistic Application of Quality by Design (QBD) for Pharma Product Development Excellence and Regulatory Compliance. Nirma Univ J Pharm Sci. 2014; 1(1): 19-35.
20. Lawrence XY, et al. Quality by Design for Generic Drugs. AAPS J. 2014; 16(4): 738-743.
21. Yu LX, Amidon G, Khan MA, Hoag SW. Understanding Pharmaceutical Quality by Design. AAPS J. 2014.
22. Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by Design: Concepts for ANDAs. The AAPS J. 2008; 10(2): 268-276.
23. Wang S, Khan MA. QBD approaches in pharmaceutical development and manufacturing. Int J Pharm Qual Assur. 2013; 4(3): 41-7.
24. Zhao L, Mao J, Frohlich H, Bousbaa H, Ierapetritou MG, Muzzio FJ. Quality by design: Experimental and computational approaches in the development of pharmaceutical processes and products. Eur J Pharm Sci. 2018; 122: 156-72.
25. Juran JM. Juran on Quality by Design: The New Steps for Planning Quality into Goods and Services. Simon and Schuster Adult Publishing Group, New York, 1991.
26. Yu LX, et al. Understanding Pharmaceutical Quality by Design. AAPS J. 2008.
27. Lawrence XY, et al. A case study published in AAPS Journal. 2008.
28. Schweitzer M, et al. QBD in Analytical Development: A Pharmaceutical Industry Perspective. Anal Bioanal Chem. 2010.
29. U.S. Food and Drug Administration (FDA). Guidance for Industry: Process Validation: General Principles and Practices. 2011.
30. FDA. Guidance for Industry: QBD for Pharmaceuticals. 2011.
31. FDA. Pharmaceutical Quality by Design: A Regulatory Perspective. 2015.
32. European Medicines Agency (EMA). Guideline on Process Validation for Finished Products: Quality by Design. 2014.
33. International Council for Harmonisation (ICH). Q8(R2) Pharmaceutical Development. 2009.
34. European Medicines Agency (EMA). Guideline on Process Validation for Finished Products. 2014.
35. Yu LX, et al. Quality by Design for Pharmaceuticals: FDA Perspective. Int J Pharm. 2008.
36. Nasr M. Risk-Based CMC Review Paradigm: Quality by Design and Process Analytical Technology. FDA Presentation, 2009.
37. FDA Guidance for Industry: PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. 2004.
38. FDA’s QBD Pilot Program. 2005.
39. EMA Guideline on Process Validation for Finished Products – Information and Data to be Provided in Regulatory Submissions. 2014.
40. ICH Q8(R2): Pharmaceutical Development, ICH Q9: Quality Risk Management, ICH Q10: Pharmaceutical Quality System.
41. Zhang L, Wu S. Quality by Design (QBD): A Review of the Role of Risk Management in Drug Development. J Pharm Sci. 2016; 105(4).
42. Wysocki J, et al. Continuous Manufacturing: A QBD Approach. Pharm Technol Eur. 2016; 28(7): 12-18.
43. DeSouza R, et al. Quality by Design for Vaccines: A Systematic Review. Biologicals. 2015; 43(6): 401-409.
44. Verma R, et al. Quality by Design for Insulin Products: Recent Advances and Future Perspectives. J Pharm Sci. 2018; 107(7).
45. Gonzalez A, et al. Artificial Intelligence in Drug Development: An Overview. J Pharm Sci. 2020; 109(10): 2867-2876.
46. Khan MZ, et al. Personalized Medicine: The Future of Pharmaceutical Quality by Design. Pharmaceutics. 2021; 13(5): 652.
47. Jiang X, et al. Quality by Design: Current and Future Perspectives. Pharm Res. 2019; 36(8): 1132-1144.